Insilico Medicine raises $95M from Aramco’s Prosperity7 Ventures

Hong Kong-based startup Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, has completed a second closing of its Series D round, led by Prosperity7 Ventures, the diversified growth fund of Aramco Ventures, bringing the total Series D financing to $95 million. Other global investors with expertise in the biopharmaceutical and life sciences sectors also participated. The new Series D capital will support the continued advancement of Insilico’s pipeline, including its lead programme which is currently in a Phase 1 study in New Zealand and in China, as well as several pipeline programmes in (Investigational New Drug) IND-enabling studies. The proceeds will also fund other key strategic initiatives, including further development of its end-to-end Pharma. AI platform, the launch of a fully automated, AIdriven robotic drug discovery laboratory and biological data factory, and the establishment of regional centres. The investment from Prosperity7 further diversifies the company’s investor base globally and brings a potential strategic partner with deep expertise in high-performance and environmentally friendly energy R&D.